Nerve repair breakthrough? tesamorelin trial aims to boost hand recovery
NCT ID NCT03150511
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This phase 2 trial tests whether tesamorelin, a daily self-injected drug, can speed nerve regrowth and reduce muscle loss after surgical repair of injured nerves in the arm. 36 adults with a cut ulnar nerve at the wrist will be randomly assigned to receive tesamorelin or no additional treatment. Researchers will measure pinch strength, hand function, and nerve signals every 3 months for a year to see if the drug improves recovery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL NERVE INJURIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sami Tuffaha
RECRUITINGBaltimore, Maryland, 21205, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tesamorelin (Egrifta) – a daily self-injected drug
What this could lead to
If it works, this could point toward a treatment that helps people recover more hand strength and sensation after nerve injury surgery.
What could go wrong
This is a small, early-phase trial with only 36 people, so results may not apply broadly. Tesamorelin is not approved for nerve injury and may have side effects like injection site reactions or affect blood sugar.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.